Affiliation:
1. Department of Cardiothoracic Surgery Weill Cornell Medicine New York NY
2. Schulich Heart Centre Division of Cardiac Surgery Department of Surgery Sunnybrook Health Sciences Centre University of Toronto Ontario Canada
3. University of Ottawa Heart Institute University of Ottawa Ontario Canada
4. Heart Department SS Annunziata Hospital Chieti Italy
5. Department of Cardiothoracic Surgery Stony Brook School of Medicine New York NY
6. Department of Cardiothoracic Surgery Mount Sinai Hospital New York NY
7. Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy
8. Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuromed Pozzilli Italy
9. Nuffield Department of Surgical Sciences University of Oxford United Kingdom
10. Mediterranea Cardiocentro Napoli Italy
Abstract
Background
Crossover dilutes treatment effect and reduces statistical power of intention‐to‐treat analysis. We examined incidence and impact on cardiac surgery randomized controlled trial (
RCT
) outcomes of crossover from experimental to control interventions, or vice versa.
Methods and Results
MEDLINE
,
EMBASE
, and Cochrane Library were searched, and
RCT
s (≥100 patients) comparing ≥2 adult cardiac surgical interventions were included. Crossover from the initial treatment assignment and relative risks (
RRs
) for each trial's primary end point and mortality at longest available follow‐up were extracted. All
RR
s were calculated as >1 favored control group and <1 favored experimental arm. Primary outcome was the effect estimate for primary end point of each
RCT
, and secondary outcome was all‐cause mortality; both were appraised as
RR
at the longest follow‐up available. Sixty articles reporting on 47
RCT
s (25 440 patients) were identified. Median crossover rate from experimental to control group was 7.0% (first quartile, 2.0%; third quartile, 9.7%), whereas from control to experimental group, the rate was 1.3% (first quartile, 0%; third quartile, 3.6%).
RR
s for primary end point and mortality were higher in
RCT
s with higher crossover rate from experimental to control group (
RR
, 1.01 [95%
CI
, 0.94–1.07] versus
RR
, 0.80 [95%
CI
, 0.66–0.97] and
RR
, 1.02 [95%
CI
, 0.95–1.11] versus
RR
, 0.94 [95%
CI
, 0.82–1.07], respectively). Crossover from control to experimental group did not alter effect estimates for primary end point or mortality (
RR
, 0.82 [95%
CI
, 0.63–1.05] versus
RR
, 0.95 [95%
CI
, 0.86–1.04] and
RR
, 0.88 [95%
CI
, 0.73–1.07] versus
RR
, 1.02 [95%
CI
, 0.95–1.09], respectively).
Conclusions
Crossover from experimental to control group is associated with outcomes of cardiac surgery
RCT
s. Crossover should be minimized at designing stage and carefully appraised after study completion.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献